Cancer patients with coronary artery disease receiving DES appear to have a primarily cancer-driven prognosis; therefore, decisions concerning DAPT and especially P2Y12 inhibitor discontinuation should prioritize cancer treatment and active chemotherapy considerations over thrombotic risk. Here, P2RY12 is linked to cancer.